Estrogen receptor-negative/progesterone receptor-positive breast cancer has distinct characteristics and pathologic complete response rate after neoadjuvant chemotherapy

Table 6 Multivariate analysis between clinical characteristics and pCR in Cohort2

Patient characteristic		B	S. E	Wals	OR	CI (95%)	P
Clinical T stage	3	Ref
	1 + 2	0.668	0.355	3.543	1.950	0.973–3.909	0.060
HR status	ER + /PR +	Ref
	ER + /PR-	0.667	0.322	4.292	1.949	1.037–3.663	0.038
	ER-/PR +	0.039	1.083	0.001	0.962	0.115–8.042	0.977
	ER-/PR-	0.992	0.237	17.523	2.697	1.695–4.292	< 0.001
HER-2	Negative	Ref
	Positive	0.721	0.200	12.956	2.057	1.389–3.046	< 0.001
KI67	≤ 15	Ref
	> 15	0.575	0.224	6.615	1.777	1.147–2.754	0.010
Stage	I + II	Ref
	III	0.520	0.321	52.415	1.682	1.075–2.631	0.023

Abbreviation: HR Hormone receptor, ER Estrogen receptor, PR Progesterone receptor, HER-2 Human epidermal growth factor receptor 2, CI Confidence interval, OR Odds ratio. Bold values indicate that they are statistically significant at P ≤ 0.05

ISSN: 1746-1596